Moreover, the combination strategy significantly promoted the infiltration of CD8+ CTL compared with shPES1 and anti-PD-1 administration alone and increased the percentage of GZMB+/CD8+ CTL in the tumor microenvironment (Fig. 7D–G). The gene discussed is CD8A; the disease is neoplasm.